A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia

Matsueda, Kei; Hongo, Michio; Tack, Jan; Saito, Youichi; Kato, Hiroki
June 2012
Gut;Jun2012, Vol. 61 Issue 6, p821
Academic Journal
Objective To determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial Methods A multicentre, randomised, placebocontrolled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acotiamide or placebo three times a day for 4 weeks, with 4 weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three mealrelated symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored. Results 52.2% of those receiving acotiamide and 34.8% in the placebo group (p<0.001) were classified as responders according to a global assessment of OTE. Over 4 weeks, the elimination rate for all three mealrelated symptoms was 15.3% among patients receiving acotiamide compared with 9.0% in the placebo group (p=0.004). The significant benefit of acotiamide over placebo in OTE and elimination rate was maintained during the 4 week post-treatment follow-up. All other secondary efficacy end points, including quality of life, were significantly improved with 100 mg of acotiamide as compared with placebo. The number needed to treat was 6 for OTE and 16 for symptom elimination rate. The incidence of adverse events was similar between the acotiamide group and placebo group and no significant cardiovascular effects due to treatment were seen. Conclusions Over 4 weeks, acotiamide significantly improved symptom severity and eliminated meal-related symptoms in patients with FD. INSET: Significance of this study.


Related Articles

  • Effects of Ethanol on the Pharmacokinetics of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02). Malhotra, Bimal; Matschke, Kyle; Wang, Qiang; Bramson, Candace; Salageanu, Joanne // Clinical Drug Investigation;Apr2015, Vol. 35 Issue 4, p267 

    Background and Objectives: ALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride (HCl), an opioid agonist, surrounding sequestered naltrexone HCl, an opioid antagonist. The objective of this study was to determine the effects of administration of...

  • Script delay best in conjunctivitis.  // Pulse;7/20/2006, Vol. 66 Issue 29, p6 

    The article reports on the effectiveness of delayed antibiotic prescribing for managing acute infective conjunctivitis, according to a new study from Great Britain. It was found that delayed prescribing reduced antibiotic use by almost 50 percent and provided similar symptom control. In...

  • Atorvastatin interaction.  // Reactions Weekly;5/19/2007, Issue 1152, p7 

    The article describes the case of a teenage boy with nephrotic syndrome who developed rhabdomyolysis during concomitant treatment with atorvastatin and prednisolone. The patient experienced pain in both of his thighs, difficulty walking and weakness of his lower extremities. The drugs were...

  • Comparative evaluation of the efficacy of two controlled release devices: Chlorhexidine chips and indigenous curcumin based collagen as local drug delivery systems. GOTTUMUKKALA, SRUTHIMA N. V. S.; SUDARSHAN, SABITHA; RAJU MANTENA, SATYANARAYANA // Contemporary Clinical Dentistry;Apr-Jun2014, Vol. 5 Issue 2, p175 

    Aim: To comparatively evaluate the therapeutic efficacy of chlorhexidine (CHX) chips (Periocol-CG) and indigenous curcumin (CU) based collagen as adjuncts to scaling and root planning in the nonsurgical management of chronic periodontitis. Materials and Methods: A total of 120 sites from 60...

  • Formulation and Evaluation of Orally Disintegrating Tablet of Nimesulide. Thulluru, Ashok; Ramesh, K. V. R. N. S.; Kumar Dinakaran, Sathis; Jana, Saikiran; Immanni, Ramarai; Doddi, Paramesh; Ankamreddy, Padmavathi // Journal of Pharmacy Research;2012, Vol. 5 Issue 6, p3204 

    Orally Disintegrating Tablets are the tablets which disintegrate rapidly in saliva, usually in a matter of seconds, without the need to take it with water. It has better patient compliance and may offer improved therapeutic efficacy, and ease of administration compared to conventional oral...

  • From the literature: Cardiovascular benefit of 'polypill' evaluated in BMJ.  // Formulary;Sep2003, Vol. 38 Issue 9, p518 

    Presents the results of a study on the efficacy of cardiovascular drugs to reduce the risk of stroke and ischemic heart disease. Meta-analysis of beta-blockers, angiotensin converting enzyme inhibitors and calcium channel blockers; Efficacy of the combination low-dose treatment.

  • Are Thiazolidinediones (TZDs) Safe? Elliott, William T. // Internal Medicine Alert;11/15/2007, Vol. 29 Issue 21, p1 

    The article reports on the results of two meta-analysis which examine the safety of the thiazolidinediones (TZD), namely rosiglitazone and pioglitazone.

  • Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case report. Abad, Nazir Hashemi; Doulatabad, Najafi Shala; Mohammadi, Ali; Ghafarian Srazi, Hamid Reza // Iranian Journal of Psychiatry;Fall2011, Vol. 6 Issue 4, p161 

    Schizophrenia and various neurological disorders have some signs and symptoms. Visual hallucinations are one of such disorders. The related studies in some diseases for example Parkinson Disease and Lewy Body Dementia indicate that Acetylcholine (Ach) plays a significant role in neuropsychiatric...

  • A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer’s Disease. Tsai, Ping-Huang; Chang, Shih-Chieh; Liu, Fang-Chun; Tsao, Jenho; Wang, Yung-Hung; Lo, Men-Tzung // Computational & Mathematical Methods in Medicine;5/18/2015, Vol. 2015, p1 

    Alzheimer’s disease (AD) is the most common form of dementia. According to one hypothesis, AD is caused by the reduced synthesis of the neurotransmitter acetylcholine. Therefore, acetylcholinesterase (AChE) inhibitors are considered to be an effective therapy. For clinicians, however,...


Read the Article


Sign out of this library

Other Topics